Korsana Biosciences announced a $175 million financing to advance a preclinical Alzheimer’s program built around a platform that delivers antibodies across the blood‑brain barrier. The company said the capital will expedite candidate optimization and IND‑enabling studies targeting neurodegenerative indications. Korsana positioned its approach alongside other industry efforts to improve CNS delivery; Roche and AbbVie have pursued similar blood‑brain barrier shuttle strategies. Korsana’s raise signals investor appetite for differentiated delivery platforms in neurology, a high‑risk, high‑need area. The company plans to use proceeds to expand R&D and prepare for early‑stage clinical development while continuing to validate CNS exposure and target engagement in preclinical models.